Anadys Pharmaceuticals/Roche
On October 17, 2011, Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) entered into a definitive merger agreement to be acquired by Roche (OTCBB: RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at $3.70 per share.
The $3.70 per share cash offer price represents a 256% premium over the closing price of $1.04 on October 14, 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Closing is expected in Q411.
The $3.70 per share cash offer price represents a 256% premium over the closing price of $1.04 on October 14, 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Closing is expected in Q411.
-
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
-
Forge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of Directors
-
Bioniz Names Veteran Biotech Leader Kleanthis G. Xanthopoulos, Ph.D. as Chairman of its Board of Directors
-
Celladon Corporation Appoints Elizabeth E. Reed General Counsel
-
Apricus Biosciences (APRI) Appoints Kleanthis Xanthopoulos as Chairman
-
Apricus Elects Kleanthis G. Xanthopoulos, Ph.D. as New Chairman
-
Wedbush Downgrades Anadys Pharmaceuticals (ANDS) to Neutral; Announces Acquisition by Roche; Additional Takeover Targets Remain
-
Unusual 11 Mid-Day Movers 10/17: (ANDS) (EP) (BEXP) Higher; (CLWR) (VECO) (CX) Lower

